MHC class I deficiency in solid tumors and therapeutic strategies to overcome it

Elena Shklovskaya; Helen Rizos

doi:10.3390/ijms22136741

MHC class I deficiency in solid tumors and therapeutic strategies to overcome it

Elena Shklovskaya^*, Helen Rizos

^*Corresponding author for this work

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Review article › peer-review

33 Citations (Scopus)

96 Downloads (Pure)

Abstract

It is now well accepted that the immune system can control cancer growth. However, tumors escape immune‐mediated control through multiple mechanisms and the downregulation or loss of major histocompatibility class (MHC)‐I molecules is a common immune escape mechanism in many cancers. MHC‐I molecules present antigenic peptides to cytotoxic T cells, and MHC‐I loss can render tumor cells invisible to the immune system. In this review, we examine the dysregulation of MHC‐I expression in cancer, explore the nature of MHC‐I‐bound antigenic peptides recognized by immune cells, and discuss therapeutic strategies that can be used to overcome MHC‐I deficiency in solid tumors, with a focus on the role of natural killer (NK) cells and CD4 T cells.

Original language	English
Article number	6741
Pages (from-to)	1-38
Number of pages	38
Journal	International Journal of Molecular Sciences
Volume	22
Issue number	13
DOIs	https://doi.org/10.3390/ijms22136741
Publication status	Published - 1 Jul 2021

Bibliographical note

Copyright the Author(s) 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

Immune checkpoint blockade
Immunotherapy
Major histocompatibility complex (MHC), MHC‐I
NK cells
Tumor antigen presentation
Tumor antigens
T‐cell subsets

Access to Document

10.3390/ijms22136741Licence: CC BY

Publisher version (open access)Final published version, 3.21 MBLicence: CC BY

Cite this

@article{ded29c12578d4786bd43b5ca9e8d851c,

title = "MHC class I deficiency in solid tumors and therapeutic strategies to overcome it",

abstract = "It is now well accepted that the immune system can control cancer growth. However, tumors escape immune‐mediated control through multiple mechanisms and the downregulation or loss of major histocompatibility class (MHC)‐I molecules is a common immune escape mechanism in many cancers. MHC‐I molecules present antigenic peptides to cytotoxic T cells, and MHC‐I loss can render tumor cells invisible to the immune system. In this review, we examine the dysregulation of MHC‐I expression in cancer, explore the nature of MHC‐I‐bound antigenic peptides recognized by immune cells, and discuss therapeutic strategies that can be used to overcome MHC‐I deficiency in solid tumors, with a focus on the role of natural killer (NK) cells and CD4 T cells.",

keywords = "Immune checkpoint blockade, Immunotherapy, Major histocompatibility complex (MHC), MHC‐I, NK cells, Tumor antigen presentation, Tumor antigens, T‐cell subsets",

author = "Elena Shklovskaya and Helen Rizos",

note = "Copyright the Author(s) 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2021",

month = jul,

day = "1",

doi = "10.3390/ijms22136741",

language = "English",

volume = "22",

pages = "1--38",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "13",

}

TY - JOUR

T1 - MHC class I deficiency in solid tumors and therapeutic strategies to overcome it

AU - Shklovskaya, Elena

AU - Rizos, Helen

N1 - Copyright the Author(s) 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2021/7/1

Y1 - 2021/7/1

N2 - It is now well accepted that the immune system can control cancer growth. However, tumors escape immune‐mediated control through multiple mechanisms and the downregulation or loss of major histocompatibility class (MHC)‐I molecules is a common immune escape mechanism in many cancers. MHC‐I molecules present antigenic peptides to cytotoxic T cells, and MHC‐I loss can render tumor cells invisible to the immune system. In this review, we examine the dysregulation of MHC‐I expression in cancer, explore the nature of MHC‐I‐bound antigenic peptides recognized by immune cells, and discuss therapeutic strategies that can be used to overcome MHC‐I deficiency in solid tumors, with a focus on the role of natural killer (NK) cells and CD4 T cells.

AB - It is now well accepted that the immune system can control cancer growth. However, tumors escape immune‐mediated control through multiple mechanisms and the downregulation or loss of major histocompatibility class (MHC)‐I molecules is a common immune escape mechanism in many cancers. MHC‐I molecules present antigenic peptides to cytotoxic T cells, and MHC‐I loss can render tumor cells invisible to the immune system. In this review, we examine the dysregulation of MHC‐I expression in cancer, explore the nature of MHC‐I‐bound antigenic peptides recognized by immune cells, and discuss therapeutic strategies that can be used to overcome MHC‐I deficiency in solid tumors, with a focus on the role of natural killer (NK) cells and CD4 T cells.

KW - Immune checkpoint blockade

KW - Immunotherapy

KW - Major histocompatibility complex (MHC), MHC‐I

KW - NK cells

KW - Tumor antigen presentation

KW - Tumor antigens

KW - T‐cell subsets

UR - http://www.scopus.com/inward/record.url?scp=85108256102&partnerID=8YFLogxK

UR - https://purl.org/au-research/grants/nhmrc/1128951

UR - https://purl.org/au-research/grants/nhmrc/1130423

U2 - 10.3390/ijms22136741

DO - 10.3390/ijms22136741

M3 - Review article

C2 - 34201655

AN - SCOPUS:85108256102

SN - 1661-6596

VL - 22

SP - 1

EP - 38

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 13

M1 - 6741

ER -

MHC class I deficiency in solid tumors and therapeutic strategies to overcome it

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Determinants of response to immune checkpoint inhibitors in melanoma

Acquired resistance to PD1 inhibition in melanoma

Cite this

MHC class I deficiency in solid tumors and therapeutic strategies to overcome it

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Projects

Determinants of response to immune checkpoint inhibitors in melanoma

Acquired resistance to PD1 inhibition in melanoma

Cite this